Возраст домена | 32 года |
Дата окончания | Истек срок регистрации |
PR | 5 |
ИКС | 20 |
Страниц в Google | 101 |
Страниц в Яндексе | 25 |
Dmoz | Да |
Яндекс Каталог | Нет |
Alexa Traffic Rank | 852532 |
Alexa Country | 259558 |
История изменения показателей | Авторизация |
better DNA - Intrexon
n/a
n/a
UTF-8
167.62 КБ
2 500
41 506 симв.
35 339 симв.
Данные предоставлены сервисом semrush
Сайт | Общие фразы | PR | тИЦ | Alexa Rank | Alexa Country | |
---|---|---|---|---|---|---|
wikipedia.org | 22 | 9 |
0 | 5 | 6 | |
linkedin.com | 17 | 9 |
0 | 25 | 10 | |
simplyhired.com | 15 | 7 |
0 | 8694 | 1923 | |
indeed.com | 10 | 8 |
0 | 138 | 50 | |
sciencemag.org | 9 | 8 |
1800 | 2334 | 954 | |
twitter.com | 9 | 10 |
0 | 11 | 8 | |
cnn.com | 8 | 9 |
0 | 104 | 24 | |
washingtonpost.com | 8 | 8 |
0 | 271 | 79 | |
glassdoor.com | 8 | 7 |
0 | 408 | 96 | |
fiercebiotech.com | 8 | 6 |
0 | 87045 | 19580 | |
dnaindia.com | 4 | 7 |
0 | 11789 | 956 | |
guardian.co.uk | 3 | 7 |
0 | 60421 | 12754 | |
pbs.org | 2 | 8 |
0 | 1716 | 378 | |
dna.ru | 2 | 3 |
40 | 2129999 | Нет данных | |
dna.gov | 2 | 6 |
0 | 7596164 | Нет данных | |
dna.fi | 2 | 6 |
0 | 33884 | 99 | |
dnalounge.com | 2 | 5 |
10 | 326338 | 73653 | |
Еще 33 сайта после авторизации |
Данные предоставлены сервисом semrush
Счетчик | Посетители за 24 часа | Просмотры | Просмотров на посетителя |
---|---|---|---|
Google Analytics | Нет доступа | Нет доступа | n/a |
Данные linkpad ( 31 Августа 2012 ) | |
Количество ссылок на сайт | 72 |
Количество доменов, которые ссылаются на сайт | 40 |
Количество найденных анкоров | 33 |
Исходящие (внешние) ссылки домена | 0 |
Количество доменов, на которые ссылается сайт | 0 |
Количество исходящих анкоров | 0 |
Внешние ссылки главной страницы ( 36 ) | |
precigen.com/pipeline/#id-prec | Precigen, Inc. |
actobio.com/ | ActoBio Therapeutics, Inc. |
bit.ly/2VGpaEK | Exemplar Genetics |
okspecialtyfruits.com/ | Okanagan Specialty Fruits, Inc. |
oxitec.com/ | Oxitec, Ltd. |
transova.com/ | Trans Ova Genetics. |
enviroflight.net/ | EnviroFlight |
ir.fibrocell.com/phoenix.zhtml?c=253777&p=irol-newsArticle&I... | Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEBMay ... |
ir.fibrocell.com/phoenix.zhtml?c=253777&p=irol-newsArticle&I... | Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene TherapyApril 15, 2... |
ir.fibrocell.com/phoenix.zhtml?c=253777&p=irol-newsArticle&I... | Fibrocell Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007October 25, 2018 Read More |
ir.fibrocell.com/phoenix.zhtml?c=253777&p=irol-newsArticle&I... | Fibrocell Awarded $1.4 Million FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis BullosaSeptember... |
ir.ziopharm.com/news-releases/news-release-details/ziopharm-... | Ziopharm Oncology Enrolls First Patient in Phase 1 Trial Evaluating Combination Therapy of Controlled IL-12 and OPDIVO®June 28, ... |
ir.ziopharm.com/news-releases/news-release-details/ziopharm-... | Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Th... |
ir.fibrocell.com/phoenix.zhtml?c=253777&p=irol-newsArticle&I... | Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic E... |
ir.ziopharm.com/news-releases/news-release-details/ziopharm-... | Ziopharm Oncology to Present Data from Clinical Studies of Controlled IL-12 in Breast Cancer and Glioblastoma at American Societ... |
ir.fibrocell.com/phoenix.zhtml?c=253777&p=irol-newsArticle&I... | Fibrocell Announces FDA Allowance of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Lo... |
ir.fibrocell.com/phoenix.zhtml?c=253777&p=irol-newsArticle&I... | Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of R... |
ir.ziopharm.com/releasedetail.cfm?ReleaseID=1053763 | Ziopharm Oncology Provides Update on Standout Technologies during the 36th Annual J.P. Morgan Healthcare ConferenceJanuary 9, 20... |
ir.ziopharm.com/releasedetail.cfm?ReleaseID=1051299 | ZIOPHARM Announces Presentation of Data from T-Cell Therapy Programs at ASH Annual MeetingDecember 10, 2017 Read More |
ir.ziopharm.com/releasedetail.cfm?ReleaseID=1049290 | ZIOPHARM Presents Positive Updated Results of Ad-RTS-hIL-12 Study in Brain Cancer at Society for Neuro-Oncology Annual MeetingNo... |
ir.ziopharm.com/releasedetail.cfm?ReleaseID=1047204 | ZIOPHARM Announces Four Presentation Abstracts at the 2017 Annual Meeting of the Society for Neuro-OncologyNovember 6, 2017 Read... |
ir.ziopharm.com/releasedetail.cfm?ReleaseID=1046508 | ZIOPHARM Announces Five Abstracts Accepted for Presentation at the 2017 American Society of Hematology Annual MeetingNovember 1,... |
businesswire.com/news/home/20171031005372/en/Agilis-Biothera... | Agilis Biotherapeutics Announces Orphan Product Designation Approval in Europe for the Treatment of Friedreich AtaxiaOctober 31,... |
ir.ziopharm.com/releasedetail.cfm?ReleaseID=1043975 | ZIOPHARM Oncology Announces First Patient Dosed in New Phase 1 Study of Ad-RTS-hIL-12 plus Veledimex for the Treatment of Pediat... |
ir.ziopharm.com/releasedetail.cfm?ReleaseID=1043670 | ZIOPHARM Announces Three Presentations at the 2017 Annual Meeting of the Society for Neuro-OncologyOctober 12, 2017 Read More |
ir.fibrocell.com/phoenix.zhtml?c=253777&p=irol-newsArticle&I... | Fibrocell Reports Interim Results of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bul... |
ir.ziopharm.com/releasedetail.cfm?ReleaseID=1040729 | ZIOPHARM Oncology Announces Updated Findings from Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma Presente... |
ir.ziopharm.com/releasedetail.cfm?ReleaseID=1038936 | ZIOPHARM Oncology to Participate at Upcoming CAR-TCR SummitSeptember 1, 2017 Read More |
oragenics.com/news-media/press-releases/detail/56/oragenics-... | Oragenics Doses First Patient in Phase 2 Clinical Trial of AG013 for Oral MucositisAugust 31, 2017 Read More |
ir.ziopharm.com/releasedetail.cfm?ReleaseID=1031586 | ZIOPHARM Oncology Announces Initiation of Stereotactic Treatment Cohort in Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurre... |
phx.corporate-ir.net/phoenix.zhtml?c=197553&p=irol-newsArtic... | AquaBounty Acquires Fish Farming Facility in IndianaJune 13, 2017 Read More |
ir.fibrocell.com/phoenix.zhtml?c=253777&p=irol-newsArticle&I... | Fibrocell Receives Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized SclerodermaJune 12, 2017 R... |
twitter.com/Intrexon?ref_src=twsrc%5Etfw | Tweets by Intrexon |
twitter.com/Intrexon | |
facebook.com/Intrexon/ | |
linkedin.com/company/intrexon-corporation | |
Внутренние ссылки главной страницы ( 48 ) | |
dna.com | intrexon |
dna.com/#pipeline-section | Our Pipeline |
dna.com/better-dna/#human-cell-tech-pane | Human Cells |
investors.dna.com/ | Investor Relations |
investors.dna.com/overview | Overview |
investors.dna.com/press | Discover More |
investors.dna.com/events | Events |
investors.dna.com/stock-information | Stock Information |
investors.dna.com/sec | SEC Filings |
investors.dna.com/corporate-governance | Corporate Governance |
investors.dna.com/investors | Investors Packet |
investors.dna.com/IRS-form-8937 | IRS Form 8937 |
dna.com/better-dna/technologies-tab-page/microbes/ | Microbes |
dna.com/better-dna/technologies-tab-page/plants/ | Plants |
dna.com/better-dna/technologies-tab-page/animals/ | Animals |
dna.com/better-dna/technologies-tab-page/human-cell-tech/ | Human Cells |
investors.dna.com/2020-01-09-Triple-Gene-Announces-Presentat... | Triple-Gene Announces Presentation at Upcoming Biotech Showcase Investor ConferenceJanuary 9, 2020- Company to Discuss First Mul... |
investors.dna.com/2020-01-06-Precigen-Receives-FDA-Orphan-Dr... | Precigen Receives FDA Orphan Drug Designation for PRGN-3006 UltraCAR-T™ in Patients with Acute Myeloid Leukemia (AML)January 6, ... |
investors.dna.com/2020-01-02-Intrexon-To-Achieve-175M-Cash-G... | Intrexon To Achieve $175M Cash Goal, Appoints Helen Sabzevari, PhD, As New President And CEO And Will Change Name To Precigen To... |
investors.dna.com/2019-11-18-Triple-Gene-Presented-Prelimina... | Triple-Gene Presented Preliminary Phase 1 Trial Data of Investigational Multigenic Therapeutic Candidate INXN‑4001 for Treatment... |
investors.dna.com/2019-11-12-Intrexon-Reports-Third-Quarter-... | Intrexon Reports Third Quarter 2019 Financial ResultsNovember 12, 2019- Tightened focus on healthcare and on track to meet yeare... |
investors.dna.com/2019-11-07-Triple-Gene-Announces-Completio... | Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN‑4001, First Multigenic Investigational Therap... |
investors.dna.com/2019-11-04-Intrexon-to-Announce-Third-Quar... | Intrexon to Announce Third Quarter Financial Results on November 12thNovember 4, 2019- Intrexon's subsidiary Precigen to host co... |
investors.dna.com/2019-09-26-David-H-Witte-to-lead-MBP-Titan... | David H. Witte to lead MBP Titan LLCSeptember 26, 2019- Former head of IHS Markit Energy, Chemicals and Agribusiness Division to... |
investors.dna.com/2019-08-19-ActoBio-Therapeutics-TM-Receive... | ActoBio Therapeutics™ Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients' ... |
investors.dna.com/2019-08-08-Intrexon-Reports-Second-Quarter... | Intrexon Reports Second Quarter and First Half 2019 Financial ResultsAugust 8, 2019- Quarterly GAAP revenues of $36.0 million an... |
investors.dna.com/2019-08-05-Precigen-Announces-First-Patien... | Precigen Announces First Patient Dosed in Phase 1 Study of PRGN-3005 UltraCAR-T™ in Patients with Advanced, Recurrent Platinum R... |
investors.dna.com/2019-08-01-Intrexon-to-Announce-Second-Qua... | Intrexon to Announce Second Quarter and First Half 2019 Financial Results on August 8thAugust 1, 2019 Read More |
investors.dna.com/2019-07-01-ActoBio-Therapeutics-TM-Progres... | ActoBio Therapeutics™ Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 DiabetesJuly 1... |
investors.dna.com/2019-06-26-Precigen-Announces-First-Patien... | Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T™ in Patients with Relapsed or Refractory Acut... |
investors.dna.com/2019-06-18-Intrexon-Corporation-and-Surter... | Intrexon Corporation and Surterra Wellness Partner in $100mm Deal to Advance Commercial Scale Fermentation-based Cannabinoid Pro... |
investors.dna.com/2019-06-13-Intrexons-Subsidiary-Precigen-t... | Intrexon's Subsidiary Precigen to Present at the JMP Securities Life Sciences ConferenceJune 13, 2019 Read More |
investors.dna.com/2019-06-03-Oxitec-Successfully-Completes-F... | Oxitec Successfully Completes First Field Deployment of 2nd Generation Friendly™ Aedes aegypti TechnologyJune 3, 2019- First fie... |
investors.dna.com/2019-06-03-Intrexon-Announces-Advances-in-... | Intrexon Announces Advances in Non-Browning GreenVenus™ Romaine LettuceJune 3, 2019Non-Browning Romaine lettuce demonstrates imp... |
investors.dna.com/2019-05-28-Intrexon-to-Participate-in-2019... | Intrexon to Participate in 2019 BIO International ConventionMay 28, 2019 Read More |
investors.dna.com/2019-05-13-Intrexon-to-Present-at-the-Bank... | Intrexon to Present at the Bank of America Merrill Lynch 2019 Healthcare ConferenceMay 13, 2019 Read More |
investors.dna.com/2019-05-09-Intrexon-Reports-First-Quarter-... | Intrexon Reports First Quarter 2019 Financial ResultsMay 9, 2019-- Quarterly GAAP revenues of $23.3 million and net loss attribu... |
investors.dna.com/2019-05-02-Intrexon-to-Release-First-Quart... | Intrexon to Release First Quarter 2019 Financial Results on May 9thMay 2, 2019 Read More |
investors.dna.com/2019-04-29-Intrexon-and-Xogenex-Present-at... | Intrexon and Xogenex Present at American Society of Gene and Cell Therapy Annual MeetingApril 29, 2019 Read More |
investors.dna.com/2019-04-25-Precigen-Opens-Gene-and-Cell-Th... | Precigen Opens Gene and Cell Therapy Manufacturing Facility in Germantown, MarylandApril 25, 2019-Nearly 5,000 square foot facil... |
investors.dna.com/2019-04-16-Oxitec-Signs-New-Multi-year-Dev... | Oxitec Signs New Multi-year Development Agreement to Apply 2nd Generation Technology to Control Soybean LooperApril 16, 2019Oxit... |
investors.dna.com/news | Discover More |
dna.com/careers/ | Join Us |
/privacy-policy | here |
careers.dna.com | Careers |
dna.com/legal-notices/ | Legal Notices |
dna.com/privacy-policy/ | Privacy Policy |
/privacy-policy/ | Click here |
Domain Name: DNA.COM
Registry Domain ID: 3972868_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.godaddy.com
Registrar URL: http://www.godaddy.com
Updated Date: 2017-08-04T12:40:42Z
Creation Date: 1991-08-05T04:00:00Z
Registry Expiry Date: 2019-08-04T04:00:00Z
Registrar: GoDaddy.com, LLC
Registrar IANA ID: 146
Registrar Abuse Contact Email: abuse@godaddy.com
Registrar Abuse Contact Phone: 480-624-2505
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: NS39.DOMAINCONTROL.COM
Name Server: NS40.DOMAINCONTROL.COM
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2018-09-25T15:02:00Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.
TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.
The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.
User-agent: *
Disallow: /wp-admin/
Allow: /wp-admin/admin-ajax.php
США - 199.48.144.20
Applied Operations, LLC
Applied Operations, LLC
HTTP/1.1 200 OK
Server: nginx
Date: Fri, 10 Jan 2020 21:30:23 GMT
Content-Type: text/html; charset=UTF-8
Content-Length: 171642
Connection: keep-alive
Keep-Alive: timeout=20
Vary: Accept-Encoding
Vary: Accept-Encoding
Link: ; rel="https://api.w.org/"
Link: ; rel=shortlink
X-Powered-By: WP Engine
X-Cacheable: SHORT
Vary: Accept-Encoding,Cookie
Cache-Control: max-age=600, must-revalidate
X-Cache: HIT: 3
X-Pass-Why:
X-Cache-Group: normal
Accept-Ranges: bytes
Кнопка для анализа сайта в один клик, для установки перетащите ссылку на "Панель закладок"